From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

Study results demonstrated that among 72 patients lymphoma receiving axicabtagene ciloleucel CAR T-cell therapy—49 with diffuse large B-cell lymphoma—those with circulating tumor DNA (ctDNA) concentrations < 10 or 10-100 lymphoma genomes per mL (LG/mL) pre-lymphodepletion had significantly better progression-free survival and overall survival than those with ctDNA concentrations > 100 LG/mL.

Journal of Clinical Oncology
Advertisement
News & Literature Highlights

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management

Leukemia

Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

OncoImmunology

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

Cancers

Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Journal of Clinical Oncology

Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective Elderly Project of the Fondazione Italiana Linfomi

British Journal of Haematology

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Journal of Clinical Oncology

Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

Advertisement
Advertisement